← Cassava Sciences, Inc. (SAVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cassava Sciences, Inc. (SAVA)
Pharmaceutical Preparations · market cap $102M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Cassava Sciences (SAVA) is a 30-employee Austin-based pharmaceutical company whose sole clinical asset, simufilam, was discontinued in November 2024 after failing to demonstrate clinical benefit in Phase 3 Alzheimer's disease trials. The company now trades at approximately $2.12 with a market cap of ~$102M, carries no active pipeline, no analyst coverage, and no upcoming catalysts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Simufilam | Phase 3 | Alzheimer Disease |
| Simufilam 100 mg oral tablet | Phase 2 | Alzheimer Disease |
| Simufilam 100 mg tablet | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-36.1%
6-month
-1.9%
12-month
-24.8%
52-wk range
$1.19–$4.64
vs 50-day MA
+0.1%
vs 200-day MA
-15.6%
Realized vol
96.3%
Max drawdown
-96.6%
Daily closes through 2026-03-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SAVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.